Lilly to be China's 'fastest-growing' pharma without M&A if new launches follow Cialis' success
This article was originally published in Scrip
Executive Summary
Eli Lilly has become the latest firm to join a wave of expansion by global pharma companies in China. At a media roundtable in Beijing, chairman, president and CEO John Lechleiter revealed that the company is planning to launch at least a dozen new drugs in the country over the next five years.